Bethany J Horton
Biographic Data
| ID | 7885391 |
|---|---|
| NAME | Bethany J Horton |
| GIVEN NAMES | Bethany J |
| FAMILY NAME | Horton |
| SIGNATURE | HORTON B J |
| AFFILIATIONS | University of Virginia |
| ORCID | 0000-0002-6866-4626 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints
Immunotherapy and chemotherapy combinations have proven to be a safe and efficacious treatment approach in multiple settings. However, it is not clear whether approved doses of chemotherapy developed to achieve a maximum tolerated dose are the ideal dose when combining cytotoxic chemotherapy with immunotherapy to induce immune responses. This trial of a modulated dose chemotherapy and Pembrolizumab, with or without a second immunomodulatory agent…
No prominent works on this page.
Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints
Immunotherapy and chemotherapy combinations have proven to be a safe and efficacious treatment approach in multiple settings. However, it is not clear whether approved doses of chemotherapy developed to achieve a maximum tolerated dose are the ideal dose when combining cytotoxic chemotherapy with immunotherapy to induce immune responses. This trial of a modulated dose chemotherapy and Pembrolizumab, with or without a second immunomodulatory agent…
Cancer (1 work) · Cancer Genomics and Diagnostics (1 work) · Cancer Immunotherapy and Biomarkers (1 work) · Chemotherapy (1 work) · Clinical trial (1 work) · Cohort (1 work) · Drug (1 work) · Immunotherapy (1 work) · Internal Medicine (1 work) · Lung cancer (1 work)